RA Capital Lifts Artiva Stake to 37.9% with $5.7M in Fresh Buys
ARTV has more than doubled off its 52-week low of $2.22.
Summary
RA Capital Management raised its stake in Artiva Biotherapeutics to 37.9% through $5.7 million in open market purchases, extending a pattern of heavy accumulation by major investors.
Key Events · Ownership and Investor Activity · ARTV
-
RA Capital Acquires 604K Shares
In open market transactions between June 16 and July 23, 2026, RA Capital bought 604,333 shares at prices ranging from $8.62 to $10.00, for a total outlay of approximately $5.7 million.
-
Stake Rises to 37.9%
After the purchases, RA Capital's aggregate ownership climbed to 18,415,956 shares, representing 37.9% of Artiva's outstanding common stock.
-
Continued Accumulation Post-Offering
The buying continues a pattern of heavy accumulation by RA Capital and other insiders following a $300 million public offering in May 2026, reinforcing confidence in the company's clinical prospects.
-
Purchases Near Current Price
The most recent purchases were made at prices up to $10.00, close to the current stock price of $10.13, indicating the fund's willingness to buy at market levels.
Analysis · ARTV · Life Sciences
Between June 16 and July 23, 2026, RA Capital—a major institutional investor with board representation—acquired an additional 604,333 shares for roughly $5.7 million, paying as much as $10.00 per share. The buying lifts its total position to 18.4 million shares, or 37.9% of the company. Coming on the heels of a $300 million public offering in May and a series of large insider purchases, the spree signals deep institutional conviction in Artiva's autoimmune pipeline. With the latest trades executed near the current $10.13 level, the fund appears to see further upside.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $10.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $492.2M. The 52-week trading range was $2.22 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.